Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS

Status unconfirmed · Not applicable

Conditions studied: Relapsing-Remitting Multiple Sclerosis

In brief

MS has been associated with fatigue, attention problems, and a number of cognitive difficulties. There is no treatment approved yet to treat these problems. We hypothesize that the addition of Provigil to an existing immunomodulatory agent (Avonex) will lead to improved fatigue, attention, and overall cognition in MS patients with attention problems.

Key facts

Study ID
NCT00210301
Run by
Institute for Clinical Research
People needed
60
Starts
2003-01-01
Last updated by the study team
2006-09-07

Who can join

Age: 20 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.